Literature DB >> 15936073

S100P is selectively upregulated in tumor cell lines challenged with DNA cross-linking agents.

Fen Jiang1, Keith Shults, Leanne Flye, Yuko Hashimoto, Riet Van Der Meer, Jingping Xie, Vladimir Kravtsov, James Price, David R Head, Robert C Briggs.   

Abstract

Bifunctional alkylating agents that cross-link DNA are implicated in the pathogenesis of therapy related myelodysplastic syndromes (MDS) and MDS related acute myeloid leukemia (MDR-AML). We exposed HL60 cells to the highest level of bifunctional alkylating nitrogen mustard mechlorethamine (HN2) that was consistent with recovery following suppressed growth. Microarray analyses showed minor changes in transcripts in HN2 treated cells. A moderate up-regulation of S100P mRNA was consistently observed after 1 day of exposure to bifunctional alkylating agents and expression was not induced with monofunctional agents. Elevated S100P protein/antigen was not detected until days later in a subset of non-mitotic G2 cells. Elevated S100P protein persisted over the course of a delayed recovery phase. The results confirm recent reports indicating that S100P is a survival factor. In addition, our results indicate that S100P has a specific role in G2 cell function associated with a prolonged phase of recovery after exposure to bifunctional alkylating agents.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15936073     DOI: 10.1016/j.leukres.2005.03.012

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  3 in total

Review 1.  Calcium-binding protein S100P and cancer: mechanisms and clinical relevance.

Authors:  Hongfei Jiang; Hang Hu; Xiaomei Tong; Qiuhong Jiang; Haiyan Zhu; Songying Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2011-09-24       Impact factor: 4.553

2.  17alpha-Hydroxylase/17,20 lyase inhibitor VN/124-1 inhibits growth of androgen-independent prostate cancer cells via induction of the endoplasmic reticulum stress response.

Authors:  Robert D Bruno; Tony D Gover; Angelika M Burger; Angela M Brodie; Vincent C O Njar
Journal:  Mol Cancer Ther       Date:  2008-09       Impact factor: 6.261

Review 3.  S100 Proteins in Acute Myeloid Leukemia.

Authors:  Annette K Brenner; Øystein Bruserud
Journal:  Neoplasia       Date:  2018-10-23       Impact factor: 5.715

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.